Whether immune activation contributes to ADC efficacy in prostate cancer remains unexplored.<h4>Methods</h4>We applied immune-centric design principles to ADC development targeting six transmembrane epithelial antigen of the prostate 1 (STEAP1), a prostate-lineage restricted, androgen receptor-regulated surface antigen. The gene discussed is STEAP1; the disease is Familial prostate cancer.